Physician profile
Walter Warren Virkus
NPI 1780663484
$276,884.96
in general payments reported to CMS, 2019-2025
7 companies · $127K in 2025
The $127K reported for 2025 was more than what 97% of Orthopaedic Trauma providers received nationally (typical 2025 total: $1,227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $30K · 2021: $32K · 2022: $32K · 2023: $11K · 2024: $24K · 2025: $127K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $127K · Consulting Fee: $29K · Travel and Lodging: $5,660 · Food and Beverage: $738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $127,361.96 |
| Consulting Fee | $29,217.25 |
| Travel and Lodging | $5,660.30 |
| Food and Beverage | $737.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $276,169.62 | 2019-2025 | Pangea, Axsos, T2 Alpha |
| Synthes Gmbh | $250.00 | 2020 | |
| Novastep INC. | $239.05 | 2022 | |
| Zimmer Biomet Holdings, INC. | $89.11 | 2019 | |
| Depuy Synthes Sales INC. | $75.20 | 2024-2025 | Attune |
| Illuminoss Medical, INC. | $61.98 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,270,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Virkus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.